News Center

With the tenet of "Healthy China, Dedicated commitment", Linuo Pharmaceuticals increases cooperation and association with external scientific research institutes while innovating and developing independently.

Corporate News

Staff Style

Home page

2025

Diverse integration, driving change forward! Licon Pharmaceutical showcased at the Second Ecological Partner Conference of Beijing Tongrentang Commercial Investment Group!

Classification：

News

行业新闻

Corporate News

214th-16th of the month,The 2nd Ecological Partner Conference of Beijing Tongrentang Commercial Investment Group was grandly held in Xiamen, themed "Diverse Integration, Riding the Change Forward," attracting over a hundred leading enterprises from the upstream and downstream of the pharmaceutical industry. Keyuan Pharmaceutical (stock code: 301281.SZ) and Linuo Pharmaceutical were invited to attend with their heavyweight new products, protein succinate iron and ambroxol hydrochloride drops, to explore new paths for collaborative development in the pharmaceutical industry with Beijing Tongrentang Commercial Investment Group and industry partners, laying a solid foundation for future deep cooperation.

Relying on a century-old brand accumulation, Beijing Tongrentang Commercial Investment Group owns hundreds of chain pharmacies covering the whole country and a mature terminal service system, making it a benchmark enterprise in the pharmaceutical retail field. Linuo Pharmaceutical has a rich product pipeline and strong production capacity in chronic disease areas such as cardiovascular, hypoglycemic, and central nervous system, with several core varieties passing the national consistency evaluation, possessing strong market advantages in production capacity and quality control.

At the conference, Jiang Hongsheng, Chairman of Keyuan Pharmaceutical, was invited to participate in the launch ceremony of "Welcoming Spring, Winning the Future - Together Welcoming the Spring of the Pharmaceutical Market," lighting up the "Spring Chapter" symbolizing industry recovery and innovation together with industry leaders. The current pharmaceutical industry is in a "golden window period" of policy dividend release, accelerated technological innovation, and upgraded market demand. Keyuan Pharmaceutical and Linuo Pharmaceutical will leverage their own R&D and production advantages, work with ecological partners, deepen industry chain collaboration, accelerate layout in high-value tracks, and inject new momentum into the high-quality development of the industry.

Keyuan Pharmaceutical and Linuo Pharmaceutical's participation in this conference provides an opportunity for deep cooperation between the two parties. In the future, Beijing Tongrentang Commercial Investment Group will utilize its retail channel advantages to provide a broader market space for Linuo Pharmaceutical's products; while Linuo Pharmaceutical will fully leverage its large-scale production capacity to enrich the Western medicine product line of Beijing Tongrentang Commercial Investment Group, providing consumers with more comprehensive and professional health services.

Looking forward to the early implementation and effectiveness of the cooperation between the two parties, ultimately achieving a "triple win" for consumers, enterprises, and the industry.

Last article

Gathering ideas and pooling efforts! Lianhe Pharmaceutical held a seminar to promote key work for 2025!

Accurate implementation and efficient advancement! Linuo Pharmaceutical held a special meeting to deeply study and implement the spirit of the group meeting!